A Wall Street research shop has taken a swing at drug discovery, and it brought an AI model instead of a lab coat.

Citrini Research, working with Anthropic, used the Claude Science model to hunt for potential scorpion antivenom candidates. The experiment produced roughly a year's worth of early-stage design work in a matter of days. It then produced something analysts care about even more: an investment thesis.

From a 35-Page Prompt to Lab Results

Citrini's analysts fed Claude Science a detailed prompt of approximately 35 pages. The model returned roughly 180 candidate molecules aimed at neutralizing scorpion toxins.

According to the research findings, work of that scope would normally take a year using traditional methods. Citrini compressed it into a short window.

That is where Twist Bioscience, a synthetic biology company, came in. The lab synthesized and tested 211 designs, of which 17 successfully bound to the target toxins.

Seventeen hits might not sound like a blowout. In early-stage drug discovery, where most candidates fail, it was enough to beat Citrini's own expectations.

The Bottleneck Moves From Software to the Lab

On October 20, 2026, Citrini published a report laying out what it learned. The core argument is less about the AI itself and more about what happens after the AI finishes its work.

If computational design gets dramatically faster, the slow part of the process shifts. The constraint is no longer coming up with candidates; it becomes testing them. Molecules can now be proposed at software speed, but synthesizing and validating them still happens at the pace of the bench.

Citrini's report frames this as a shift in the drug development story. Attention moves away from computational design tools and toward physical experimental validation and the lab infrastructure that supports it. The firm's thesis is that these companies are likely to see rising demand for experimental validation services.

The report singled out two names as top picks: Charles River Laboratories International Inc., a contract research organization that runs preclinical and early-stage testing for drug developers, and Revvity Inc., a life-sciences and diagnostics company serving research and lab workflows.

Part of a Bigger Pharma Push Into AI

Novo Nordisk, one of the world's largest drugmakers, struck a partnership with Anthropic in September 2026, a deal that signaled that large pharmaceutical companies are taking AI-assisted research seriously.

The Citrini test adds a different kind of data point. It came from outside the pharma establishment, from analysts whose day job is picking stocks. If a research firm can generate validated binders with a long prompt and an AI model, the barrier to early-stage design looks lower than it used to.

What This Means for Investors and the Industry

The obvious AI trade is to buy the companies building the models. Citrini's report argues for a less obvious one: buying the businesses that sit downstream of the and absorb the extra work they create.

There are reasons to keep expectations measured. The Citrini result covers a single target, scorpion antivenom toxins, and binding to a toxin is an early milestone. It is a long way from a binder in a lab to a treatment in a hospital, and candidates that bind still face optimization, safety testing, and clinical trials.

The findings also note that a heavier emphasis on physical validation adds complexity to the supply chain. More molecules mean more synthesis, more testing, and more coordination between design teams and labs. How demand for synthesis and testing capacity develops from here could serve as an early test of the report's thesis.